Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of h...
FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Find More
Molluscum contagiosum, often known as water warts, is a common superficial skin disease caused by the poxvirus. The molluscum contagiosum virus (MCV) is one of the world's 50 most common diseases. It mostly affects school-aged children, sexually active young adults, and immunocompromised people. As per our...
Find More
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history and low healing rates. Despite current management therapies, the disease has the potential to become severe and devastating for many patients over time. Dystrophic epidermolysis bullosa is classified into six types: dominant dyst...
Find More
Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...
Find More
FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...
Find More
Burn is a global public health problem, causing more than 180,000 deaths per year across the world. The vast majority of these occur in low- and middle-income nations. Moreover, non-fatal burns are a primary source of morbidity, resulting in lengthy hospitalization, deformity, and disability, as well as stigma and ...
Find More
Collagen Matrix received FDA 510(k) approval for Fibrillar Collagen Wound Dressing On June 29, 2022, Collagen Matrix, Inc., a leader in regenerative medicine, a global manufacturer of collagen and other biomaterial-based medical devices, and Linden Capital Partners portfolio company announced FDA 510(k) Clearan...
Find More
A Burn takes place when the skin comes into contact with a heat source. Burns can occur from many different sources. The most common sources that cause Burns are fire/flame, scalds, hot objects, electrical, and chemical agents, respectively. Burns is a common injury seen in emergency departments around the world. E...
Find More
GSK Starts Preparations for Regulatory Filings as RSV Vaccine Clears Phase III Test in Adults GSK plans to initiate preparation for regulatory submissions for its respiratory syncytial virus (RSV) vaccine after the vaccine performed well in the much-anticipated AReSVi 006 trial in individuals aged 60 and above.&...
Find More
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....
Find More
A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 mi.....
Find More
Rheumatoid Arthritis (RA) is an inflammatory disorder that affects an individual's single or multipl.....
Find More
The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....
Find More
Managing patients virtually, the most important healthcare trend of 2020, is a process where healthc.....
Find More
Celiac disease is an autoimmune disorder against the gluten consumed that creates toxins, thereby, d.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
